125 related articles for article (PubMed ID: 38569857)
1. [Multiple myeloma with IgH::MYC and multiple extramedullary lesions].
Sasaki Y; Ichikawa S; Sakurai K; Nakamura H; Inokura K; Onodera K; Fukuhara N; Onishi Y; Yokoyama H; Harigae H
Rinsho Ketsueki; 2024; 65(3):147-152. PubMed ID: 38569857
[TBL] [Abstract][Full Text] [Related]
2. MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes.
Yamamoto K; Yakushijin K; Ito M; Goto H; Higashime A; Kajimoto K; Hayashi Y; Matsuoka H; Minami H
Cancer Genet; 2020 Apr; 242():35-40. PubMed ID: 32035866
[TBL] [Abstract][Full Text] [Related]
3. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
[TBL] [Abstract][Full Text] [Related]
4. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
5. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
6. A novel five-way translocation, t(3;9;13;8;14)(q27;p13;q32;q24;q32), with concurrent MYC and BCL6 rearrangements in a primary bone marrow B-cell lymphoma.
Yamamoto K; Matsuoka H; Yakushijin K; Funakoshi Y; Okamura A; Hayashi Y; Minami H
Cancer Genet; 2011 Sep; 204(9):501-6. PubMed ID: 22018272
[TBL] [Abstract][Full Text] [Related]
7. The novel double-hit, t(8;22)(q24;q11)/MYC-IGL and t(14;15)(q32;q24)/IGH-BCL2A1, in diffuse large B-cell lymphoma.
Akasaka T; Kishimori C; Fukutsuka K; Nakagawa M; Takeoka K; Hayashida M; Honjo G; Ohno H
Cancer Genet; 2017 Aug; 214-215():26-31. PubMed ID: 28595732
[TBL] [Abstract][Full Text] [Related]
8. PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).
Sato K; Sakai H; Kato M; Nishio Y; Tsuruoka Y; Uemura Y; Yokoi S; Saito T; Matsunawa M; Suzuki Y; Isobe Y; Inoue Y; Takahashi M; Miura I
Int J Hematol; 2015 Jun; 101(6):608-11. PubMed ID: 25633778
[TBL] [Abstract][Full Text] [Related]
9. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics.
Bink K; Haralambieva E; Kremer M; Ott G; Beham-Schmid C; de Leval L; Peh SC; Laeng HR; Jütting U; Hutzler P; Quintanilla-Martinez L; Fend F
Haematologica; 2008 Apr; 93(4):623-6. PubMed ID: 18326524
[TBL] [Abstract][Full Text] [Related]
10. Double-Hit Primary Plasma Cell Leukemia with
Yasumi M; Endo T; Sata H; Karasuno T
Case Rep Hematol; 2020; 2020():8811114. PubMed ID: 33381329
[TBL] [Abstract][Full Text] [Related]
11. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
13. [Aggressive B-cell lymphoma with IGH/MYC, IGH/BCL2, and IGH/CCND1 translocations].
Nishijima A; Noguchi Y; Narukawa K; Takano H; Oshikawa G
Rinsho Ketsueki; 2019; 60(10):1425-1430. PubMed ID: 31695002
[TBL] [Abstract][Full Text] [Related]
14. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of a cytogenetically complex Chinese multiple myeloma-derived cell line with homozygous p53 deletion and cyclin E overexpression.
Cheng SH; Ng MH; Tsang KS; Lau KM; Chan JC; Liu HS; Chu RW; Poon CS; Ng HK
Int J Oncol; 2004 May; 24(5):1141-8. PubMed ID: 15067335
[TBL] [Abstract][Full Text] [Related]
17. Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies.
Farre L; Sanz G; Ruiz-Xivillé N; Castro de Moura M; Martin-Tejera JF; Gonçalves-Ribeiro S; Martinez-Iniesta M; Calaf M; Luis Mosquera J; Martín-Subero JI; Granada I; Esteller M; Domingo-Domenech E; Climent F; Villanueva A; Sureda A
Dis Model Mech; 2021 Jul; 14(7):. PubMed ID: 33988237
[TBL] [Abstract][Full Text] [Related]
18. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
Avet-Loiseau H; Li JY; Facon T; Brigaudeau C; Morineau N; Maloisel F; Rapp MJ; Talmant P; Trimoreau F; Jaccard A; Harousseau JL; Bataille R
Cancer Res; 1998 Dec; 58(24):5640-5. PubMed ID: 9865713
[TBL] [Abstract][Full Text] [Related]
19. [Multiple myeloma with variant type translocation, t(8;22)(q24;q11.2)].
Sugiyama A; Nakabayashi H; Kondo M; Tominaga T; Shinohara K
Rinsho Ketsueki; 2009 Jan; 50(1):29-33. PubMed ID: 19225226
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
